{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:23:30Z","timestamp":1792801410293,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40263-016-0393-9","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T09:38:21Z","timestamp":1478597901000},"page":"1127-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson\u2019s Disease: Therapeutic Rationale and Current Status"],"prefix":"10.1007","volume":"30","author":[{"given":"Tara","family":"Swart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"393_CR1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/0140-6736(90)91006-V","volume":"335","author":"CD Marsden","year":"1990","unstructured":"Marsden CD. Parkinson\u2019s disease. Lancet. 1990;335:948\u201352.","journal-title":"Lancet."},{"key":"393_CR2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Dis. 2014;29:1583\u201390.","journal-title":"Mov Dis."},{"key":"393_CR3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Dis. 2015;30:1591\u2013601.","journal-title":"Mov Dis."},{"key":"393_CR4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science."},{"key":"393_CR5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson\u2019s disease. Science. 2003;302:841.","journal-title":"Science."},{"key":"393_CR6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature."},{"key":"393_CR7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging."},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","volume":"134","author":"K Kalinderi","year":"2016","unstructured":"Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson\u2019s disease: current progress and future prospects. Acta Neurol Scand. 2016;134:314\u201326. doi: 10.1111\/ane.12563 .","journal-title":"Acta Neurol Scand"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jnc.13593","volume":"139","author":"DG Hernandez","year":"2016","unstructured":"Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-mendelian inheritance. J Neurochem. 2016;139:59\u201374. doi: 10.1111\/jnc.13593 .","journal-title":"J Neurochem"},{"key":"393_CR10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","volume":"1","author":"AH Schapira","year":"1989","unstructured":"Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. Lancet. 1989;1:1269.","journal-title":"Lancet."},{"key":"393_CR11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biol Med. 2013;62:132\u201344.","journal-title":"Free Radical Biol Med."},{"key":"393_CR12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/cne.21974","volume":"513","author":"FA Azevedo","year":"2009","unstructured":"Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol. 2009;513:532\u201341.","journal-title":"J Comp Neurol."},{"key":"393_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2003.04.001","volume":"25","author":"H Braak","year":"2004","unstructured":"Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging. 2004;25:19\u201323.","journal-title":"Neurobiol Aging."},{"key":"393_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35036035","volume":"1","author":"MJ Berridge","year":"2000","unstructured":"Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1:11\u201321.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"393_CR15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10495-010-0465-0","volume":"15","author":"H B\u00fceler","year":"2010","unstructured":"B\u00fceler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson\u2019s disease. Apoptosis. 2010;15:1336\u201353.","journal-title":"Apoptosis."},{"key":"393_CR16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbagrm.2010.07.006","volume":"1809","author":"AN Hegde","year":"2011","unstructured":"Hegde AN, Upadhya SC. Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta. 2011;1809:128\u201340.","journal-title":"Biochim Biophys Acta."},{"key":"393_CR17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pharmthera.2011.11.006","volume":"133","author":"MJ Hurley","year":"2012","unstructured":"Hurley MJ, Dexter DT. Voltage-gated calcium channels and Parkinson\u2019s disease. Pharmacol Ther. 2012;133:324\u201333.","journal-title":"Pharmacol Ther."},{"key":"393_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","volume":"460","author":"A Lau","year":"2010","unstructured":"Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010;460:525\u201342.","journal-title":"Pflugers Arch."},{"key":"393_CR19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mito.2010.05.014","volume":"10","author":"ME Witte","year":"2010","unstructured":"Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion. 2010;10:411\u20138.","journal-title":"Mitochondrion."},{"key":"393_CR20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1089\/ars.2010.3521","volume":"14","author":"DJ Surmeier","year":"2011","unstructured":"Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. The origins of oxidant stress in Parkinson\u2019s disease and therapeutic strategies. Antioxid Redox Signal. 2011;14:1289\u2013301.","journal-title":"Antioxid Redox Signal."},{"key":"393_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)91236-A","volume":"526","author":"T Yamada","year":"1990","unstructured":"Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson\u2019s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990;526:303\u20137.","journal-title":"Brain Res."},{"key":"393_CR22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.1992.tb24523.x","volume":"648","author":"DC German","year":"1992","unstructured":"German DC, Manaye KF, Sonsalla PK, Brooks BA. Midbrain dopaminergic cell loss in Parkinson\u2019s disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci. 1992;648:42\u201362.","journal-title":"Ann N Y Acad Sci."},{"key":"393_CR23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/brain\/122.8.1421","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999;122:1421\u201336.","journal-title":"Brain."},{"key":"393_CR24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(89)90328-5","volume":"104","author":"K Fujimura","year":"1989","unstructured":"Fujimura K, Matsuda Y. Autogenous oscillatory potentials in neurons of the guinea pig substantia nigra pars compacta in vitro. Neurosci Lett. 1989;104:53\u20137.","journal-title":"Neurosci Lett."},{"key":"393_CR25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. \u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease. Nature. 2007;447:1081\u20136.","journal-title":"Nature."},{"key":"393_CR26","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1523\/JNEUROSCI.0143-10.2010","volume":"30","author":"ZM Khaliq","year":"2010","unstructured":"Khaliq ZM, Bean BP. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci. 2010;30:7401\u201313.","journal-title":"J Neurosci."},{"key":"393_CR27","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nn.3209","volume":"15","author":"JA Goldberg","year":"2012","unstructured":"Goldberg JA, Guzman JN, Estep CM, Ilijic E, Kondapalli J, Sanchez-Padilla J, et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson\u2019s disease. Nat Neurosci. 2012;15:1414\u201321.","journal-title":"Nat Neurosci."},{"key":"393_CR28","doi-asserted-by":"crossref","first-page":"a009290","DOI":"10.1101\/cshperspect.a009290","volume":"2","author":"DJ Surmeier","year":"2012","unstructured":"Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT. Physiological phenotype and vulnerability in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a009290.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"393_CR29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468:696\u2013700.","journal-title":"Nature."},{"key":"393_CR30","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/mds.22801","volume":"25","author":"CS Chan","year":"2010","unstructured":"Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson\u2019s disease. Mov Disord. 2010;25:S63\u201370.","journal-title":"Mov Disord."},{"key":"393_CR31","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991;114:2283\u2013301.","journal-title":"Brain."},{"key":"393_CR32","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1523\/JNEUROSCI.2519-09.2009","volume":"29","author":"JN Guzman","year":"2009","unstructured":"Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci. 2009;29:11011\u20139.","journal-title":"J Neurosci."},{"key":"393_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1523\/JNEUROSCI.4341-06.2007","volume":"27","author":"M Puopolo","year":"2007","unstructured":"Puopolo M, Raviola E, Bean BP. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci. 2007;27:645\u201356.","journal-title":"J Neurosci."},{"key":"393_CR34","doi-asserted-by":"publisher","unstructured":"Surmeier DJ, Schumacker PT, Guzman JD, Ilijic E, Yang B, Zampese E. Calcium and Parkinson\u2019s disease. Biochem Biophys Res Commun. 2016. doi: 10.1016\/j.bbrc.2016.08.168 .","DOI":"10.1016\/j.bbrc.2016.08.168"},{"key":"393_CR35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","volume":"70","author":"C Becker","year":"2008","unstructured":"Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70:1438\u201344.","journal-title":"Neurology."},{"key":"393_CR36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","volume":"67","author":"B Ritz","year":"2010","unstructured":"Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67:600\u20136.","journal-title":"Ann Neurol."},{"key":"393_CR37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0896-6273(90)90135-3","volume":"4","author":"MK Ahlijanian","year":"1990","unstructured":"Ahlijanian MK, Westenbroek RE, Catterall WA. Subunit structure and localization of dihydropyridine-sensitive calcium channels in mammalian brain, spinal cord, and retina. Neuron. 1990;4:819\u201332.","journal-title":"Neuron."},{"key":"393_CR38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0306-4522(95)00514-5","volume":"71","author":"NC Day","year":"1996","unstructured":"Day NC, Shaw PJ, McCormack AL, Craig PJ, Smith W, Beattie R, et al. Distribution of alpha 1A, alpha 1B and alpha 1E voltage-dependent calcium channel subunits in the human hippocampus and parahippocampal gyrus. Neurosci. 1996;71:1013\u201324.","journal-title":"Neurosci."},{"key":"393_CR39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.123.4.949","volume":"123","author":"JW Hell","year":"1993","unstructured":"Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, et al. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J Cell Biol. 1993;123:949\u201362.","journal-title":"J Cell Biol."},{"key":"393_CR40","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1073\/pnas.93.8.3362","volume":"93","author":"JW Hell","year":"1996","unstructured":"Hell JW, Westenbroek RE, Breeze LJ, Wang KK, Chavkin C, Catterall WA. N-methyl-d-aspartate receptor-induced proteolytic conversion of postsynaptic class C L-type calcium channels in hippocampal neurons. Proc Natl Acad Sci USA. 1996;93:3362\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"393_CR41","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1073\/pnas.88.16.7076","volume":"88","author":"D Hillman","year":"1991","unstructured":"Hillman D, Chen S, Aung TT, Cherksey B, Sugimori M, Llinas RR. Localization of P-type calcium channels in the central nervous system. Proc Natl Acad Sci USA. 1991;88:7076\u201380.","journal-title":"Proc Natl Acad Sci USA."},{"key":"393_CR42","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/brain\/awt134","volume":"136","author":"MJ Hurley","year":"2013","unstructured":"Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson\u2019s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain. 2013;136:2077\u201397.","journal-title":"Brain."},{"key":"393_CR43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s12031-014-0410-8","volume":"55","author":"MJ Hurley","year":"2015","unstructured":"Hurley MJ, Gentleman SM, Dexter DT. Calcium CaV1 channel subtype mRNA expression in Parkinson\u2019s disease examined by in situ hybridization. J Mol Neurosci. 2015;55:715\u201324.","journal-title":"J Mol Neurosci."},{"key":"393_CR44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1523\/JNEUROSCI.17-04-01339.1997","volume":"17","author":"A Ludwig","year":"1997","unstructured":"Ludwig A, Flockerzi V, Hofmann F. Regional expression and cellular localization of the alpha1 and beta subuni of high voltage-activated calcium channels in rat brain. J Neurosci. 1997;17:1339\u201349.","journal-title":"J Neurosci."},{"key":"393_CR45","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1523\/JNEUROSCI.4846-03.2004","volume":"24","author":"JE McRory","year":"2004","unstructured":"McRory JE, Hamid J, Doering CJ, Garcia E, Parker R, Hamming K, et al. The CACNA1F gene encodes an L-type calcium channel with unique biophysical properties and tissue distribution. J Neurosci. 2004;24:1707\u201318.","journal-title":"J Neurosci."},{"key":"393_CR46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/350398a0","volume":"350","author":"Y Mori","year":"1991","unstructured":"Mori Y, Friedrich T, Kim MS, Mikami A, Nakai J, Ruth P, et al. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature. 1991;350:398\u2013402.","journal-title":"Nature."},{"key":"393_CR47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1523\/JNEUROSCI.3327-04.2005","volume":"25","author":"PA Olson","year":"2005","unstructured":"Olson PA, Tkatch T, Hernandez-Lopez S, Ulrich S, Ilijic E, Mugnaini E, et al. G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. J Neurosci. 2005;25:1050\u201362.","journal-title":"J Neurosci."},{"key":"393_CR48","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.neuroscience.2010.02.037","volume":"167","author":"B Schlick","year":"2010","unstructured":"Schlick B, Flucher BE, Obermair GJ. Voltage-activated calcium channel expression profiles in mouse brain and cultured hippocampal neurons. Neurosci. 2010;167:786\u201398.","journal-title":"Neurosci."},{"key":"393_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.108.049981","volume":"75","author":"MJ Sinnegger-Brauns","year":"2009","unstructured":"Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009;75:407\u201314.","journal-title":"Mol Pharmacol."},{"key":"393_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-0102(02)00204-3","volume":"45","author":"Y Takahashi","year":"2003","unstructured":"Takahashi Y, Jeong SY, Ogata K, Goto J, Hashida H, Isahara K, et al. Human skeletal muscle calcium channel alpha1S is expressed in the basal ganglia: distinctive expression pattern among L-type Ca2+ channels. Neurosci Res. 2003;45:129\u201337.","journal-title":"Neurosci Res."},{"key":"393_CR51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cne.21567","volume":"506","author":"AL Tippens","year":"2008","unstructured":"Tippens AL, Pare JF, Langwieser N, Moosmang S, Milner TA, Smith Y, et al. Ultrastructural evidence for pre- and postsynaptic localization of CaV1.2 L-type Ca2+ channels in the rat hippocampus. J Comp Neurol. 2008;506:569\u201383.","journal-title":"J Comp Neurol."},{"key":"393_CR52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0169-328X(95)00234-J","volume":"34","author":"SG Volsen","year":"1995","unstructured":"Volsen SG, Day NC, McCormack AL, Smith W, Craig PJ, Beattie R, et al. The expression of neuronal voltage-dependent calcium channels in human cerebellum. Mol Brain Res. 1995;34:271\u201382.","journal-title":"Mol Brain Res."},{"key":"393_CR53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/347281a0","volume":"347","author":"RE Westenbroek","year":"1990","unstructured":"Westenbroek RE, Ahlijanian MK, Catterall WA. Clustering of L-type Ca2+ channels at the base of major dendrites in hippocampal pyramidal neurons. Nature. 1990;347:281\u20134.","journal-title":"Nature."},{"key":"393_CR54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0896-6273(92)90069-P","volume":"9","author":"RE Westenbroek","year":"1992","unstructured":"Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099\u2013115.","journal-title":"Neuron."},{"key":"393_CR55","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1523\/JNEUROSCI.15-10-06403.1995","volume":"15","author":"RE Westenbroek","year":"1995","unstructured":"Westenbroek RE, Sakurai T, Elliott EM, Hell JW, Starr TV, Snutch TP, et al. Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J Neurosci. 1995;15:6403\u201318.","journal-title":"J Neurosci."},{"key":"393_CR56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.physiol.66.032102.113328","volume":"66","author":"JS Trimmer","year":"2004","unstructured":"Trimmer JS, Rhodes KJ. Localization of voltage-gated ion channels in mammalian brain. Ann Rev Physiol. 2004;66:477\u2013519.","journal-title":"Ann Rev Physiol."},{"key":"393_CR57","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1152\/physrev.00002.2008","volume":"88","author":"H Vacher","year":"2008","unstructured":"Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev. 2008;88:1407\u201347.","journal-title":"Physiol Rev."},{"key":"393_CR58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.410230316","volume":"23","author":"DL Watson","year":"1988","unstructured":"Watson DL, Carpenter CL, Marks SS, Greenberg DA. Striatal calcium channel antagonist receptors in Huntington\u2019s disease and Parkinson\u2019s disease. Ann Neurol. 1988;23:303\u20135.","journal-title":"Ann Neurol."},{"key":"393_CR59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0006-8993(93)90505-H","volume":"611","author":"AP Sen","year":"1993","unstructured":"Sen AP, Boksa P, Quirion R. Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer\u2019s, Parkinson\u2019s and Huntington\u2019s diseases. Brain Res. 1993;611:216\u201321.","journal-title":"Brain Res."},{"key":"393_CR60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398.","journal-title":"Lancet Neurol."},{"key":"393_CR61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0006-8993(86)91207-2","volume":"377","author":"N Nishino","year":"1986","unstructured":"Nishino N, Noguchi-Kuno SA, Sugiyama T, Tanaka C. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson\u2019s disease. Brain Res. 1986;377:186\u20139.","journal-title":"Brain Res."},{"key":"393_CR62","first-page":"9","volume":"9","author":"YC Lee","year":"2014","unstructured":"Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson\u2019s disease: a nationwide cohort study. PLoS One. 2014;9:9.","journal-title":"PLoS One."},{"key":"393_CR63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","volume":"175","author":"B Pasternak","year":"2012","unstructured":"Pasternak B, Svanstr\u00f6m H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson\u2019s disease. Am J Epidemiol. 2012;175:627\u201335.","journal-title":"Am J Epidemiol."},{"key":"393_CR64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","volume":"33","author":"ED Louis","year":"2009","unstructured":"Louis ED, Benito-Le\u00f3n J, Bermejo-Pareja F, Neurological Disorders in Central Spain (NEDICES) Study Group. Antihypertensive agents and risk of Parkinson\u2019s disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiol. 2009;33:286\u201392.","journal-title":"Neuroepidemiol"},{"key":"393_CR65","first-page":"CD008535","volume":"9","author":"K Rees","year":"2011","unstructured":"Rees K, Stowe R, Patel S, Ives N, Breen K, Ben-Shlomo Y, et al. Anti-hypertensive drugs as disease-modifying agents for Parkinson\u2019s disease: evidence from observational studies and clinical trials. Cochrane Database Syst Rev. 2011;9:CD008535.","journal-title":"Cochrane Database Syst Rev."},{"key":"393_CR66","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","volume":"25","author":"KC Simon","year":"2010","unstructured":"Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson\u2019s disease. Mov Disord. 2010;25:1818\u201322.","journal-title":"Mov Disord."},{"key":"393_CR67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","volume":"13","author":"TG Ton","year":"2007","unstructured":"Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, et al. Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13:165\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"393_CR68","first-page":"697404","volume":"2015","author":"K Gudala","year":"2015","unstructured":"Gudala K, Kanukula R, Bansal D. Reduced risk of Parkinson\u2019s disease in users of calcium channel blockers: a meta-analysis. Int J Chronic Dis. 2015;2015:697404.","journal-title":"Int J Chronic Dis."},{"key":"393_CR69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3781","volume":"24","author":"Y Lang","year":"2015","unstructured":"Lang Y, Gong D, Fan Y. Calcium channel blocker use and risk of Parkinson\u2019s disease: a meta-analysis. Pharmacoepidemiol Drug Saf. 2015;24:559\u201366.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"393_CR70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.1063395","volume":"294","author":"RE Dolmetsch","year":"2001","unstructured":"Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science. 2001;294:333\u20139.","journal-title":"Science."},{"key":"393_CR71","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1152\/jn.00486.2004","volume":"92","author":"D Lipscombe","year":"2004","unstructured":"Lipscombe D, Helton TD, Xu W. L-type calcium channels: the low down. J Neurophysiol. 2004;92:2633\u201341.","journal-title":"J Neurophysiol."},{"key":"393_CR72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11481-014-9568-7","volume":"10","author":"SC Hopp","year":"2015","unstructured":"Hopp SC, Royer SE, D\u2019Angelo HM, Kaercher RM, Fisher DA, Wenk GL. Differential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the substantia nigra and locus coeruleus. J Neuroimmune Pharmacol. 2015;10:35\u201344.","journal-title":"J Neuroimmune Pharmacol."},{"key":"393_CR73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.neuropharm.2008.10.016","volume":"56","author":"Y Li","year":"2009","unstructured":"Li Y, Hu X, Liu Y, Bao Y, An L. Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacol. 2009;56:580\u20139.","journal-title":"Neuropharmacol."},{"key":"393_CR74","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.molimm.2009.10.013","volume":"47","author":"Y Suzuki","year":"2010","unstructured":"Suzuki Y, Inoue T, Ra C. L-type Ca2+ channels: a new player in the regulation of Ca2+ signaling, cell activation and cell survival in immune cells. Mol Immunol. 2010;47:640\u20138.","journal-title":"Mol Immunol."},{"key":"393_CR75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fendo.2013.00158","volume":"4","author":"JW Wright","year":"2013","unstructured":"Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Endocrinol (Lausanne). 2013;4:158.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"393_CR76","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/HYPERTENSIONAHA.111.171249","volume":"57","author":"C Qiu","year":"2011","unstructured":"Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, et al. Association of blood pressure and hypertension with the risk of Parkinson\u2019s disease: the National FINRISK Study. Hypertension. 2011;57:1094\u2013100.","journal-title":"Hypertension."},{"key":"393_CR77","doi-asserted-by":"crossref","unstructured":"Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease. Nat Commun. 2012;3:1146.","DOI":"10.1038\/ncomms2149"},{"key":"393_CR78","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00001756-199503000-00009","volume":"6","author":"A Kupsch","year":"1995","unstructured":"Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 1995;6:621\u20135.","journal-title":"Neuroreport."},{"key":"393_CR79","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(96)00917-1","volume":"741","author":"A Kupsch","year":"1996","unstructured":"Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996;741:185\u201396.","journal-title":"Brain Res."},{"key":"393_CR80","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","volume":"43","author":"E Ilijic","year":"2011","unstructured":"Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson\u2019s disease. Neurobiol Dis. 2011;43:364\u201371.","journal-title":"Neurobiol Dis."},{"key":"393_CR81","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","volume":"28","author":"Parkinson Study Group","year":"2013","unstructured":"Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson\u2019s disease (STEADY-PD). Mov Disord. 2013;28:1823\u201331.","journal-title":"Mov Disord."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0393-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:34:33Z","timestamp":1718886873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0393-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]}}}